MARCELO ARAUJO QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease(2022) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; CAPARELI, Fernanda C.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.Purpose: To analyze the associations between positron emission tomography (PET)/magnetic resonance imaging (MRI) features for primary rectal tumors and metastases. Procedures: Between November 2016 and April 2018, 101 patients with rectal adenocarcinoma were included in this prospective study (NCT02537340) for whole-body PET/MRI for baseline staging. Two readers analyzed the PET/MRI; they assessed the semiquantitative PET features of the primary tumor and the N- and M-stages. Another reader analyzed the MRI features for locoregional staging. The reference standard for confirming metastatic disease was biopsy or imaging follow-up. Nonparametric tests were used to compare the PET/MRI features of the participants with or without metastatic disease. Binary logistic regression was used to evaluate the associations between the primary tumor PET/MRI features and metastatic disease. Results: A total of 101 consecutive participants (median age 62 years; range: 33-87 years) were included. Metastases were detected in 35.6% (36 of 101) of the participants. Among the PET/MRI features, higher tumor lesion glycolysis (352.95 vs 242.70; P =.46) and metabolic tumor volume (36.15 vs 26.20; P =.03) were more frequent in patients with than in those without metastases. Additionally, patients with metastases had a higher incidence of PET-positive (64% vs 32%; P =.009) and MRIpositive (56% vs 32%; P =.03) mesorectal lymph nodes, extramural vascular invasion (86% vs 49%; P >.001), and involvement of mesorectal fascia (64% vs 42%; P =.04); there were also differences between the mrT stages of these two groups (P =.008). No differences in the maximum standardized uptake values for the primary tumors in patients with and without metastases were observed (18.9 vs 19.1; P =.56). Multivariable logistic regression showed that extramural vascular invasion on MRI was the only significant predictor (adjusted odds ratio, 3.8 [95% CI: 1.1, 13.9]; P =.001). Conclusion: PET/MRI facilitated the identification of participants with a high risk of metastatic disease, though these findings were based mainly on MRI features.
- Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients(2021) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.Purpose We compared the diagnostic accuracy of detecting distant metastases for baseline rectal cancer staging between PET/MRI and conventional staging (CS). Materials and methods This prospective study from November 2016 to April 2018 included 101 rectal adenocarcinoma patients for primary staging. These patients underwent whole-body PET/MRI in addition to CS (pelvic MRI and thoracic and abdominal contrast-enhanced CT). Different readers analyzed CS and PET/MRI findings for primary tumor, nodal, and metastatic staging. The presence, number, and location of metastases were recorded according to the organ involved (non-regional lymph nodes (LNs), liver, lungs, or others). Lesions were defined as positive, negative, or indeterminate. The number of lesions per organ was limited to 10. The McNemar test was used to compare the accuracies. Results PET/MRI exhibited a higher accuracy in detecting metastatic disease than CS in all patients (88.4% vs. 82.6%,p = 0.003) and in patients with extramural vascular invasion (EMVI) (88.9% vs. 85.5%,p = 0.013). The detection rate of PET/MRI was superior to that of CS for all lesions [84.1% vs. 68.9%,p = 0.001], as well as those in the liver (89.2% vs. 84.2%), non-regional LNs (90.0% vs. 36.7%), and lungs (76.4% vs. 66.9%). PET/MRI correctly classified 19/33 (57.5%) patients with indeterminate lesions on CS. Conclusion PET/MRI yields higher accuracy than CS for detecting distant synchronous metastases in the baseline staging of patients with rectal cancer and EMVI. PET/MRI exhibited a higher detection rate than CS for identifying non-regional LNs, hepatic lesions, and pulmonary lesions as well as correctly classifying patients with indeterminate lesions.
- Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease (vol 24, pg 453, 2021)(2022) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; CAPARELI, Fernanda C.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.
conferenceObject PET/MR for staging rectal cancer: a comparison to conventional staging with pelvic MR and thoracoabdominal CT(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; BLASBALG, R.; NAHAS, S.; CERRI, G. G.; BUCHPIGUEL, C.